(Q33388402)

26 July 2017

title

The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

Luca Antonio Aldrighetti

5

object named as

Luca Aldrighetti

1 reference

26 July 2017

Stefano Cereda

1

1 reference

26 July 2017

Paolo Passoni

2

1 reference

26 July 2017

Michele Reni

3

1 reference

26 July 2017

Maria G Viganò

4

1 reference

26 July 2017

Roberto Nicoletti

6

1 reference

26 July 2017

Eugenio Villa

7

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

26 July 2017

1 reference

26 July 2017

volume

116

1 reference

26 July 2017

issue

9

1 reference

26 July 2017

page(s)

2208-2214

1 reference

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

21 January 2018

Biliary tract cancers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Eastern cooperative oncology group experience with chemotherapy for inoperable gallbladder and bile duct cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

A phase II study of cisplatin in patients with biliary tract carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Phase II study of erlotinib in patients with advanced biliary cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Interaction between gemcitabine and mitomycin-C in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Phase II study of cisplatin, epirubicin, and continuous-infusion 5-fluorouracil for advanced biliary tract cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Comprehensive criteria for assessing therapy-induced toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24970

7 January 2021

Identifiers

DOI

10.1002/CNCR.24970

1 reference

26 July 2017

1 reference